New Study Shows Vapotherm Hi-VNI® Technology Improved In-patient Participant Ambulation Recovery Time by 32.5% Versus Standa...
November 01 2019 - 4:30PM
Business Wire
- Study found that Hi-VNI Technology during ambulation is
feasible
- Hi-VNI Technology improved recovery time amongst these patients
by 32.5% versus standard oxygen therapy
- Hi-VNI Technology improved patient distance walked by 12.4% and
duration of time walked by 8.5%. vs. standard oxygen therapy
amongst the inpatient group of these patients
Vapotherm, Inc. (NYSE: VAPO), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology, today announced that a paper
published in the Journal of Clinical Respiratory Diseases and Care,
titled “Assessing the Clinical Effect of High Velocity Nasal
Insufflation on Improving Ambulation in Patients with Dyspnea: A
Feasibility Study” demonstrated that use of Vapotherm Hi-VNI
Technology during ambulation is feasible and showed that patients
with dyspnea participating in this study who used Hi-VNI Technology
as respiratory support walked farther and recovered faster when
compared to standard oxygen treatment.
“These results show that the Vapotherm Transfer Unit not only
provides support for hospital transfers across all deparments, but
also offers an important respiratory support option for clinicians
managing inpatients requiring ambulation as part of their
treatment,” said Joe Army, President and CEO of Vapotherm. “This
study offers an additional proof point for clinicians that Hi-VNI
Technology may help their patients, not just in general settings as
Mask-Free NIV™ for spontaneously breathing patients, but also
during ambulation and recovery.”
The feasibility study was a prospective cross-over trial that
compared oxygen treatment as usual (TAU) to treatment with Hi-VNI
Technology—which delivers high velocity nasal insufflation
(HVNI)—in 28 patients during ambulation in both inpatient and
outpatient settings. The goal was to compare how far and for how
long patients could ambulate on Hi-VNI Technology versus the
standard TAU. Vital signs and recovery time were measured as
secondary outcomes. 25 of the 28 patients were analyzed.
Among the inpatients in this study, Hi-VNI Technology during
ambulation was not only feasible, but also showed improved patient
distance walked by 12.4% and duration of time walked by 8.5%. It
also improved recovery time by 32.5%. Use was also feasible among
outpatients undergoing ambulation, although outpatients performed
worse than the inpatient subgroup studied.
These results are very encouraging for further research as well
as demonstrating feasibility of using Hi-VNI Technology in
respiratory patient ambulation.
While this study was comparing Hi-VNI Technology to oxygen
support, previous studies have demonstrated that Hi-VNI Technology
is comparable to noninvasive positive pressure ventilation (NiPPV)
when treating patients in undifferentiated respiratory distress.
The Vapotherm Transfer Unit is a self contained mobile means of
delivering Hi-VNI Technology for patients on the move in the acute
setting.
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded
developer and manufacturer of advanced respiratory technology based
in Exeter, New Hampshire, USA. The company develops innovative,
comfortable, non-invasive technologies for respiratory support of
patients with chronic or acute breathing disorders. Over 2.0
million patients have been treated with Vapotherm Hi-VNI
Technology. For more information, visit www.vapotherm.com.
Hi-VNI® Technology is mask-free noninvasive ventilation
for spontaneously breathing patients and a front-line tool for
relieving respiratory distress—including hypercapnia, hypoxemia,
and dyspnea. It allows for the fast, safe treatment of
undifferentiated respiratory distress with one user-friendly tool.
Hi-VNI Technology’s mask-free interface delivers optimally
conditioned breathing gases, making it comfortable for patients and
reducing the risks and care complexities associated with mask
therapies. While being treated, patients can talk, eat, drink and
take oral medication.
Website Information Vapotherm routinely posts important
information for investors on the Investor Relations section of its
website, http://investors.vapotherm.com/. Vapotherm intends to use
this website as a means of disclosing material, non-public
information and for complying with Vapotherm’s disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the Investor Relations section of Vapotherm’s website, in
addition to following Vapotherm’s press releases, Securities and
Exchange Commission filings, public conference calls, presentations
and webcasts. The information contained on, or that may be accessed
through, Vapotherm’s website is not incorporated by reference into,
and is not a part of, this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191101005575/en/
Greg Ramade VP of Marketing +1-(603)-658-0011, ext. 188 or
+1-(603)-658-0628 pr@vtherm.com
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Apr 2023 to Apr 2024